Application | Comment | Organism |
---|---|---|
drug development | 11beta-HSD1 will significantly contribute to the biotransformation of oracin in humans. The microsomal carbonyl reductase has a great potential to significantly impair the chemotherapy with the anticancer drug oracin | Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.042 | - |
oracin | - |
Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
membrane | - |
Homo sapiens | 16020 | - |
microsome | - |
Homo sapiens | - |
- |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Purification (Comment) | Organism |
---|---|
solubilization, partially purifed by gel filtration, 73fold | Homo sapiens |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
liver | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
oracin + NADPH + H+ | the partially purified enzyme catalyzes the reduction of oracin in a stereospecific manner and with higher efficiency and affinity compared to microsomal 11beta-HSD1. The enzyme purified from human liver reduces oracin to (-)-dihydrooracin and (+)-dihydrooracin in a ratio of 76 to 24. Whole human liver microsomes metabolise oracin with different stereospecificity, where the formation of (-)-dihydrooracin (60%) predominates over (+)-dihydrooracin (40%) | Homo sapiens | 11-dihydrooracin + NADP+ | - |
? |
Synonyms | Comment | Organism |
---|---|---|
11beta-HSD1 | - |
Homo sapiens |
11beta-hydroxysteroid dehydrogenase type 1 | - |
Homo sapiens |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NADPH | specific for | Homo sapiens |